Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
32
resultados
Última actualización
20/09/2024 [08:29:00]
Resumen de: US2024310389A1
This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).
Resumen de: US2024302372A1
The present disclosure describes methods of determining a treatment protocol for and/or a prognosis for a subject suspected of or at risk of suffering from a neurologic disease or disorder, including such diseases and disorders that involve motor neuron function such as ALS. The methods comprise detecting the presence of a chitinase protein in a biological sample.
Resumen de: CN118234849A
The present disclosure provides multicellular culture models for studying neuroinflammation, e.g., to identify new targets, biomarkers, and therapeutic agents for the diagnosis, prognosis, and treatment of neurodegenerative diseases. Further provided herein are assays for studying neuroinflammation using the cell culture models of the invention.
Resumen de: US2024301046A1
The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
Resumen de: US2024301050A1
The present invention relates to a novel binding molecule with excellent preventive, ameliorative or therapeutic effects on a brain and nervous system disease and uses thereof. The binding molecule provided in the present invention can effectively prevent or treat brain and nervous system diseases, particularly neurodegenerative diseases or neuroinflammatory diseases.
Resumen de: WO2024184494A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2023073384A1
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
Resumen de: WO2023077153A1
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein-associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.
Resumen de: CN118251224A
The present invention provides methods and compositions for treating subjects suffering from dementia with Lewy bodies (DLB) but without significant tauopathies. DLB subjects without significant tauopathy exhibit a particular response to treatment with a selective p38 alpha mitogen-activated protein kinase (MAPK) inhibitor as compared to DLB subjects with significant tauopathy.
Resumen de: US2023287422A1
The present disclosure provides methods of treating subjects having Alzheimer's Disease, and methods of identifying subjects having an increased risk of developing Alzheimer's Disease.
Resumen de: AU2022354161A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
Resumen de: AU2022408967A1
Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAXTM effectively improved the sensory function in patients with diabetic neuropathy.
Resumen de: US2024295570A1
Provided herein are isolated BIN1 SH3 domain proteins and methods for their use to identify candidate Alzheimer's disease therapeutics.
Resumen de: US2024294624A1
The present invention concerns the field of monoclonal antibodies, and describes an isolated anti-EPO antibody which binds human Erythropoietin (EPO) preventing its binding to specific receptors and inhibiting their signaling pathway. The invention further describes a polynucleotide encoding the anti-EPO antibody, a vector comprising the polynucleotide and a host cell comprising the vector. Furthermore, a method is described, for producing the antibody. The compounds of the invention, alone or in combination, are effective in the treatment of proliferative disorders such as cancers, where they cause the induction of apoptosis and overcome drug-resistance in cancer cells, cancer stem cells and in tumor endothelial cells, of autoimmune and non-autoimmune based chronic inflammatory diseases, in the treatment of patients undergoing organ or tissue transplant, in the treatment of haemophilic arthropathy, neurodegenerative diseases and neurological diseases in which neuro inflammation plays a role in pathogenesis, for example: multiple sclerosis, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, autoimmune disease with neurologic involvement, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases, ophthalmic pathologies such as neovascular age related (NVAMD), macular degeneration, retinal vein occlusion (RVO), metabolic syndromes, diabetes, and neuropathic pain disorders and the invention described compositions comprising them and medical
Resumen de: US2024294620A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Resumen de: US2024294621A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Resumen de: EP4424704A2
The present invention relates to a marker for determining a cerebral Aβ accumulation state, the marker comprising a combination of a ratio of Aβ1-40 (SEQ ID NO.: 2) level to Aβ1-42 (SEQ ID NO.: 3) level: Aβ1-40/Aβ1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to Aβ1-42 (SEQ ID NO.: 3) level: APP669-711/Aβ1-42, in a living body-derived sample, as well as to respective analytical methods for determining a cerebral Aβ accumulation state, for determining efficacy of a medical intervention regarding a cerebral Aβ accumulation state, and for predicting progression of symptoms in future or predicting a risk of development of dementia regarding a cerebral Aβ accumulation state.
Resumen de: US2024067707A1
The invention provides anti-Tau antibodies and methods of using the same.
Resumen de: AU2023216231A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Resumen de: AU2022439338A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: CN116064763A
The invention relates to the field of disease diagnosis and treatment, in particular to disease diagnosis and treatment with IFP35 and NMI as targets. The invention discloses application of interferon-induced protein 35kD and/or detection of N-Myc interaction protein in diagnosis or prognosis evaluation of inflammatory bowel diseases, arthritis, psoriasis, systemic lupus erythematosus, nervous system diseases, lung injury and peritonitis, in evaluation of the severity of arthritis and in distinguishing of tumor diseases and thoracic infection diseases for the first time. The ROC curve chart shows that the interferon-induced protein 35kD and/or the N-Myc interaction detection protein can be used as a marker for diagnosis or prognosis evaluation of inflammatory bowel diseases, arthritis, psoriasis, systemic lupus erythematosus, nervous system diseases, lung injury and peritonitis, evaluation of the severity of arthritis and distinguishing of tumor diseases and thoracic infection diseases.
Resumen de: US2024285727A1
Described herein is a novel, mitochondrial encoded, open reading frame that leads to the production of a new mitochondrial peptide called SHMOOSE. SHMOOSE is a 58-amino-acid peptide and, within its open reading frame, contains a genome-wide significant small nucleotide polymorphism (SNP) that markedly increased risk for Alzheimer's disease, brain structure, brain gene expression, and cognition. SHMOOSE increased neuronal-type cell survival and protected against amyloid beta toxicity. Metabolomic studies revealed a role for the peptide in energy optimization, whose dysfunction and dysregulation leads to cell death in physiologically notable regions of the brain in neurodegenerative diseases such as Alzheimer's and Parkinson's. Methods and compositions, including peptide analogues and derivatives, are described for treatment and diagnostics.
Resumen de: WO2024177086A1
Provided is a method for evaluating dementia risk, the method allows direct understanding of the physical state of a subject through an analysis of a biological sample of the subject, and objective and highly accurate evaluation of the risk of the subject who might be developing dementia (mild cognitive impairment (MCI) or Alzheimer's disease (AD)). Concentration data regarding an element group for evaluation in a blood (plasma or serum) sample 2 taken from a subject are acquired (step S1), the concentration data are applied to a discriminant function that determines whether the subject belongs to a control group or a case group, and a correlation between concentrations of the group of elements for evaluation is calculated (step S2), and on the basis of the correlation, an indicator as to whether the subject is suffering from dementia is obtained (step S3). As the group of elements for evaluation, a combination of the 17 elements Na, Mg, P, S, K, Ca, Fe, Co, Cu, Zn, As, Se, Rb, Sr, Mo, Ag, and Cs is used. It is preferable that an estimation that the type of dementia that the subject is suffering from is MCI or AD is included in evaluation results.
Resumen de: US2024287471A1
The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.
Nº publicación: EP4419918A1 28/08/2024
Solicitante:
NEURO BIO LTD [GB]
Neuro-Bio Ltd
Resumen de: AU2022354161A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
BOPI
Sede Electrónica
